KR-27452
KR-27452 is a selective and orally active PI4KIIIβ inhibitor with an IC50 of 0.026 μM, while showing no activity against PI4KIIIα (IC50 >10 μM) . KR-27452 specifically binds to and inhibits PI4KIIIβ, leading to reduced viral replication in cells. KR-27452 exhibits strong antiviral activity against human rhinovirus (RVs) and Coxsackievirus (COXs) . KR-27452 can be used for the research of infection[1].
Product Specifications
UNSPSC
12352005
Target
Enterovirus; PI4K
Related Pathways
Anti-infection; PI3K/Akt/mTOR
Applications
COVID-19-anti-virus
Field of Research
Infection
Smiles
O=C(N(CCCO)C)C1=CC(C2=C(C)N=C(NC(CC3=CC=CC=C3)=O)S2)=CC=C1OC
Molecular Formula
C24H27N3O4S
Molecular Weight
453.55
References & Citations
[1]Ayele SA, et al. 2-amido-3-aryl-4-methyl-thiazole derivatives as broad-spectrum anti-rhinoviral agents. Eur J Med Chem. 2026;302 (Pt 3) :118318.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PI4KIIIβ
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Mucin 1 / EMA / Episialin / CD227 (VU-2G7), CF568 conjugate, 0.1mg/mL
CD31 / PECAM-1 (158-2B3), CF640R conjugate, 0.1mg/mL
